Efficacy and safety of larotrectinib in patients with TRK‑fusion tumor


MUDr. Kateřina Kopečková, Ph.D.

Onkologická klinika 2. LF UK a FN v Motole, Praha



Larotrectinib is a registered anticancer drug for antitumor therapy for tumors with NTRK gene fusions. A published analysis of 159 adult and pediatric patients with solid NTRK fusion tumors treated with larotrectinib showed a median duration of response of 35.2 months and a median time to disease progression of 28.3 months. These were highly heterogeneous groups of advanced pretreated tumors. Larotrectinib has a good safety profile; the dose was reduced in 8% of patient, in 2% due to side effects.


Key words

larotrectinib, NTRK fusions, tumor-agnostic treatment



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...